Skip to content

Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer

Detection of Breast Lesions Utilizing iBreast Exam: A Comparison With Clinical Breast Exam

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04761055
Enrollment
309
Registered
2021-02-18
Start date
2021-01-29
Completion date
2025-08-19
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Screening

Keywords

Breast Abnormalities

Brief summary

This study will test the iBreastExam device to find out whether it can detect a mass or lump in the breast as accurately as a routine breast cancer screening examination. The iBreastExam is a handheld device that performs a painless electronic palpation (examination by touch) of the breast. The device is designed to detect breast abnormalities that may require breast imaging and additional clinical examination by a nurse or doctor. The iBreastExam device creates a color map of the breast, with red spots indicating areas that may be abnormal.

Interventions

OTHERClinical Breast exam (CBE)

The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.

DEVICEiBreastExam device

The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.

DIAGNOSTIC_TESTmammogram

All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.

Sponsors

UE LifeSciences Inc.
CollaboratorINDUSTRY
Earlier.org
CollaboratorUNKNOWN
Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female patient * Over 18 years of age, able to consent * RLC patients presenting to RLC or BAIC for mammogram and CBE * Asymptomatic and symptomatic patients will be included

Exclusion criteria

* Male patients * Patients under 18 years of age, unable to consent * Pregnant patients * Lactating patients * Non-intact skin

Design outcomes

Primary

MeasureTime frameDescription
Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations (CBE)by Estimating the Sensitivity of the Device Using Imaging Resultsapproximately one month after imaging scancomparing the calculated the sensitivities or the percentage of true positive breast lesions (based on imaging results) of the iBE and CBE
Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations by Estimating the Specificity of the Device Using Imaging Resultsapproximately one month after imaging scancomparing the calculated the specificities or the percentage of true negative lesions (based on imaging results) of the iBE and CBE

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026